classical Hodgkin’s lymphoma

May 19, 2016May 19, 2016

FDA Approves Opdivo (nivolumab) to Treat Advanced Classical Hodgkin Lymphoma

News

The U.S. Food and Drug Administration (FDA) has approved Opdivo (nivolumab), a PD-1 inhibitor, for the treatment of classical Hodgkin lymphoma (cHL) in patients who relapsed or progressed after autologous hematopoietic stem ... Read more

April 20, 2016April 20, 2016

FDA Approves Breakthrough Therapy Designation for Hodgkin’s Lymphoma Treatment Keytruda

News

The FDA has granted Merck’s anti-PD-1 therapy Keytruda (pembrolizumab), Breakthrough Therapy Designation (BTD) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin’s lymphoma (cHL). The FDA previously granted BTD ... Read more

April 4, 2016May 13, 2016

EMA Agrees to Consider Opdivo (nivolumab) as a Possible Treatment for Classical Hodgkin’s Lymphoma

News

Bristol-Myers Squibb announced that the European Medicines Agency (EMA) has validated its Type II variation application of Opdivo (nivolumab), which seeks to extend Opdivo’s current indications to include the treatment of classical Hodgkin’s lymphoma (cHL) patients after prior therapies. The ... Read more

September 15, 2015September 15, 2015

Classical Hodgkin’s Lymphoma More Prevalent in Treated HIV Patients

News

Individuals with human immunodeficiency virus (HIV) seem to have higher rates of lymphoma development, especially grade B-non Hodgkin lymphomas (NHL). However, these lymphomas, which are also the most common types ... Read more

May 29, 2015

Study Investigates The Role of Macrophages and Dendritic Cells in Classical Hodgkin Lymphoma

News

A new study entitled “Macrophages and Dendritic Cells as Actors in the Immune Reaction of Classical Hodgkin Lymphoma”, published in PLOS One, assessed the role of macrophages and dendritic cells ... Read more